What Is the Zantac Lawsuit?

Lawsuits stem from long-term use of Zantac (ranitidine), a once-popular heartburn medication voluntarily recalled in 2020. The active ingredient may degrade into NDMA, a probable human carcinogen—plaintiffs allege this led to cancers, especially bladder and stomach cancers. Manufacturers are accused of failing to warn users or conceal known risks.

Why Are Cases Still Pending?

• Early trial outcomes showed Plaintiff expert testimony being excluded in major courts—especially in Florida and Delaware—due to court rulings that the science linking Zantac and cancer lacked sufficient reliability.
• Courts in Delaware recently ruled that nearly 75,000 cases could not proceed because expert reports did not meet federal admissibility standards.
• Until expert testimony survives rigorous court scrutiny, many cases remain unresolved and face legal hurdles moving forward.

Scope & Ongoing Litigation

• By mid-2025, GSK resolved ~93% of its U.S. state-court cases, covering nearly 80,000 claims, for up to $2.2B.
• Sanofi settled over 10,000 cases in 2024 for between $200M–$250M.
• Pfizer also settled approximately 10,000 claims for nearly $250M.
• Boehringer Ingelheim continues to resist settlement offers and faces trials, especially in California.

Trial & Judicial Developments

• The first trial verdict in Illinois ruled against the plaintiff—an 89-year-old woman—denying her $640M claim and concluding that her colon cancer was not linked to Zantac.
• A follow-up ruling in Delaware (July 2025) overturned previous permissive rulings, excluding crucial scientific testimony in thousands of cases.
• Despite these legal headwinds, plaintiffs remain committed to pursuing trials where possible and mounting appeals.

Case Volume & Key Players

• Major Settled Claims: GSK: ~80K cases settled for up to $2.2B; Sanofi: ($200–250M); Pfizer: similar settlement.
• Pending Litigation: Ongoing cases primarily against Boehringer—in California, Delaware, and elsewhere.
• Case Volume: Roughly 100K+ plaintiffs across multiple states.

Compensation & Outlook

Settlements and Awards

• GSK settlement: capped at $2.2 billion, covering nearly all eligible claims through mid-2025.
• Sanofi & Pfizer settlements: approximately $200M–$250M each for similar claims.
• Boehringer Ingelheim: no major settlements; defendants continue litigation.

Payout Expectations

• While the GSK and Sanofi deals offer certainty, further litigation may yield significant awards for successful plaintiffs—especially in states where scientific evidence is better received.
• Appeals and admissibility rulings (e.g., in Delaware) will play a big role in shaping how other cases proceed.